Valeris Strengthens Leadership with Scott Filosi as CCO for Enhanced Commercial Strategy

Valeris Welcomes Scott Filosi as Chief Commercial Officer

In a significant move aimed at bolstering its leadership team, Valeris, a comprehensive life sciences commercialization partner, has appointed Scott Filosi as its new Chief Commercial Officer (CCO). This strategic decision reflects Valeris's commitment to enhancing its commercial strategy and expanding partner relationships across the healthcare landscape.

Who is Scott Filosi?

Scott Filosi comes to Valeris with an extensive background in commercial leadership, boasting nearly 30 years of experience in the biopharmaceutical sector. His impressive resume includes senior roles at renowned organizations, where he has made significant impacts in areas such as market access, pricing, trade, distribution, and patient services. Filosi's career has been characterized by his ability to drive transformation and build high-performing teams, showcasing his adeptness in sculpting commercial strategies that support long-term growth and market positioning.

Most recently, he served as the Head of US and Global Market Access, Pricing, and Trade at Verona Pharma. In this role, Filosi was instrumental in shaping payer access, pricing strategies, and distribution channels. Additionally, his tenure as CEO of companies like Luzsana Bio and Mirror Bio highlights his capacity to advance clinical programs and steer organizations through pivotal stages of growth while securing necessary funding. Moreover, he has offered advisory and board-level insights to emerging companies, fostering refined strategies and strengthened leadership.

Filosi also held several key leadership positions at Merck KGaA, UCB Pharma, Boehringer Ingelheim, and Johnson & Johnson, contributing to substantial product launches and brand developments. He possesses a robust knowledge of the healthcare market, making his insights invaluable as Valeris endeavors to further its mission of providing comprehensive solutions for life sciences companies.

What Filosi Will Bring to Valeris

As CCO, Filosi will oversee Valeris's commercial organization, focusing on accelerating business growth, enhancing operational execution, and broadening partner relations. His leadership is expected to propel Valeris into a new chapter of innovation and strategic execution, underscoring the company’s goal of removing barriers that patients face in accessing critical medications.

Robert Truckenmiller, the CEO of Valeris, expressed great enthusiasm about Filosi's appointment. He remarked, “Scott's leadership will sharpen our execution, accelerate innovation, and strengthen the measurable outcomes we can deliver for our partners and the patients we support.” This sentiment highlights the high expectations surrounding Filosi’s contributions toward optimizing commercialization efforts in a seeking to thrive health system.

In addition to his extensive professional background, Scott Filosi holds a Bachelor of Business Administration from Fitchburg State University and has pursued executive leadership studies at prestigious institutions such as Stanford University and INSEAD. His combination of practical experience and academic credentials positions him uniquely for this leadership role.

Valeris's Commitment to Patient Care

Valeris, headquartered in Morrisville, North Carolina, and Jeffersonville, Indiana, aims to improve the patient experience by providing strategic insights, data analytics, and patient support services. With mastery over the healthcare value chain, Valeris collaborates with over 500 life sciences companies to enhance access and affordability for millions of patients. The addition of Filosi to their leadership underscores their resolve to innovate and adapt in a rapidly changing healthcare environment.

As Scott Filosi steps into his new role, stakeholders and partners eagerly anticipate the transformations he will bring to Valeris, driving forward their mission of confident commercialization in the life sciences arena. The industry looks forward to seeing how his experience and strategic insight will enhance the services offered to clients and ultimately improve patient care outcomes.